BioMarin Pharmaceutical Inc. (BMRN)
USD 60.58
(-10.23%)
USD 60.58
(-10.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.89 Billion USD | 6.67% |
| 2022 | 1.77 Billion USD | 2.27% |
| 2021 | 1.73 Billion USD | -0.54% |
| 2020 | 1.74 Billion USD | 11.12% |
| 2019 | 1.56 Billion USD | 7.43% |
| 2018 | 1.45 Billion USD | -20.02% |
| 2017 | 1.82 Billion USD | 45.1% |
| 2016 | 1.25 Billion USD | -5.35% |
| 2015 | 1.32 Billion USD | 38.02% |
| 2014 | 962.55 Million USD | 5.99% |
| 2013 | 908.17 Million USD | 55.01% |
| 2012 | 585.88 Million USD | 10.41% |
| 2011 | 530.63 Million USD | -2.7% |
| 2010 | 545.36 Million USD | -8.34% |
| 2009 | 594.97 Million USD | -5.56% |
| 2008 | 630.02 Million USD | 0.39% |
| 2007 | 627.55 Million USD | 81.57% |
| 2006 | 345.63 Million USD | 26.71% |
| 2005 | 272.76 Million USD | -9.36% |
| 2004 | 300.94 Million USD | 117.31% |
| 2003 | 138.48 Million USD | 1047.08% |
| 2002 | 12.07 Million USD | -1.55% |
| 2001 | 12.26 Million USD | 76.73% |
| 2000 | 6.93 Million USD | 34.16% |
| 1999 | 5.17 Million USD | 146.29% |
| 1998 | 2.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.79 Billion USD | -4.83% |
| 2024 Q3 | 1437.79 Billion USD | -19.26% |
| 2024 Q2 | 1.78 Billion USD | -1.0% |
| 2023 Q4 | 1.89 Billion USD | 1.55% |
| 2023 Q3 | 1.86 Billion USD | 4.55% |
| 2023 FY | 1.89 Billion USD | 6.67% |
| 2023 Q2 | 1.78 Billion USD | 0.32% |
| 2023 Q1 | 1.77 Billion USD | 0.15% |
| 2022 Q4 | 1.77 Billion USD | 4.51% |
| 2022 Q1 | 1.67 Billion USD | -3.53% |
| 2022 Q3 | 1.69 Billion USD | 3.32% |
| 2022 Q2 | 1.64 Billion USD | -1.82% |
| 2022 FY | 1.77 Billion USD | 2.27% |
| 2021 Q2 | 1.65 Billion USD | 0.84% |
| 2021 Q1 | 1.64 Billion USD | -5.68% |
| 2021 Q4 | 1.73 Billion USD | 1.24% |
| 2021 FY | 1.73 Billion USD | -0.54% |
| 2021 Q3 | 1.71 Billion USD | 3.28% |
| 2020 Q2 | 2.06 Billion USD | 39.29% |
| 2020 Q1 | 1.48 Billion USD | -5.41% |
| 2020 Q3 | 2.1 Billion USD | 1.88% |
| 2020 FY | 1.74 Billion USD | 11.12% |
| 2020 Q4 | 1.74 Billion USD | -17.21% |
| 2019 Q4 | 1.56 Billion USD | 5.66% |
| 2019 FY | 1.56 Billion USD | 7.43% |
| 2019 Q1 | 1.49 Billion USD | 2.71% |
| 2019 Q2 | 1.43 Billion USD | -4.43% |
| 2019 Q3 | 1.48 Billion USD | 3.58% |
| 2018 Q3 | 1.78 Billion USD | 2.34% |
| 2018 Q1 | 1.78 Billion USD | -1.9% |
| 2018 FY | 1.45 Billion USD | -20.02% |
| 2018 Q2 | 1.73 Billion USD | -2.8% |
| 2018 Q4 | 1.45 Billion USD | -18.04% |
| 2017 Q4 | 1.82 Billion USD | 3.24% |
| 2017 Q3 | 1.76 Billion USD | 44.33% |
| 2017 Q2 | 1.22 Billion USD | 4.69% |
| 2017 Q1 | 1.16 Billion USD | -6.99% |
| 2017 FY | 1.82 Billion USD | 45.1% |
| 2016 Q1 | 1.37 Billion USD | 3.63% |
| 2016 Q4 | 1.25 Billion USD | 5.1% |
| 2016 Q2 | 1.16 Billion USD | -15.04% |
| 2016 FY | 1.25 Billion USD | -5.35% |
| 2016 Q3 | 1.19 Billion USD | 2.28% |
| 2015 Q1 | 1.23 Billion USD | 28.12% |
| 2015 FY | 1.32 Billion USD | 38.02% |
| 2015 Q4 | 1.32 Billion USD | -0.28% |
| 2015 Q2 | 1.29 Billion USD | 4.74% |
| 2015 Q3 | 1.33 Billion USD | 3.13% |
| 2014 Q4 | 962.55 Million USD | 3.28% |
| 2014 Q2 | 883.71 Million USD | 0.35% |
| 2014 FY | 962.55 Million USD | 5.99% |
| 2014 Q1 | 880.6 Million USD | -3.04% |
| 2014 Q3 | 931.99 Million USD | 5.46% |
| 2013 Q2 | 343.26 Million USD | -1.4% |
| 2013 Q1 | 348.14 Million USD | -40.58% |
| 2013 FY | 908.17 Million USD | 55.01% |
| 2013 Q3 | 344.04 Million USD | 0.23% |
| 2013 Q4 | 908.17 Million USD | 163.97% |
| 2012 Q1 | 525.13 Million USD | -1.04% |
| 2012 FY | 585.88 Million USD | 10.41% |
| 2012 Q4 | 585.88 Million USD | 6.1% |
| 2012 Q3 | 552.18 Million USD | 3.77% |
| 2012 Q2 | 532.1 Million USD | 1.33% |
| 2011 FY | 530.63 Million USD | -2.7% |
| 2011 Q4 | 530.63 Million USD | 1.94% |
| 2011 Q3 | 520.53 Million USD | -5.03% |
| 2011 Q1 | 543.3 Million USD | -0.38% |
| 2011 Q2 | 548.08 Million USD | 0.88% |
| 2010 Q1 | 620.96 Million USD | 4.37% |
| 2010 FY | 545.36 Million USD | -8.34% |
| 2010 Q2 | 622.55 Million USD | 0.26% |
| 2010 Q3 | 658.86 Million USD | 5.83% |
| 2010 Q4 | 545.36 Million USD | -17.23% |
| 2009 Q3 | 565.5 Million USD | 0.8% |
| 2009 FY | 594.97 Million USD | -5.56% |
| 2009 Q1 | 626.34 Million USD | -0.58% |
| 2009 Q2 | 561 Million USD | -10.43% |
| 2009 Q4 | 594.97 Million USD | 5.21% |
| 2008 Q3 | 621.13 Million USD | -1.18% |
| 2008 FY | 630.02 Million USD | 0.39% |
| 2008 Q1 | 618.53 Million USD | -1.44% |
| 2008 Q2 | 628.52 Million USD | 1.62% |
| 2008 Q4 | 630.02 Million USD | 1.43% |
| 2007 Q2 | 614.03 Million USD | 115.41% |
| 2007 Q3 | 616.51 Million USD | 0.4% |
| 2007 Q1 | 285.05 Million USD | -17.53% |
| 2007 Q4 | 627.55 Million USD | 1.79% |
| 2007 FY | 627.55 Million USD | 81.57% |
| 2006 FY | 345.63 Million USD | 26.71% |
| 2006 Q3 | 344.95 Million USD | -17.83% |
| 2006 Q2 | 419.82 Million USD | -5.06% |
| 2006 Q1 | 442.22 Million USD | 62.13% |
| 2006 Q4 | 345.63 Million USD | 0.2% |
| 2005 FY | 272.76 Million USD | -9.36% |
| 2005 Q4 | 272.76 Million USD | -0.53% |
| 2005 Q3 | 274.22 Million USD | -1.25% |
| 2005 Q2 | 277.68 Million USD | 2.4% |
| 2005 Q1 | 271.16 Million USD | -9.89% |
| 2004 Q1 | 140.52 Million USD | 1.47% |
| 2004 FY | 300.94 Million USD | 117.31% |
| 2004 Q4 | 300.94 Million USD | 0.97% |
| 2004 Q3 | 298.06 Million USD | -2.02% |
| 2004 Q2 | 304.22 Million USD | 116.49% |
| 2003 Q3 | 142.48 Million USD | -1.02% |
| 2003 Q2 | 143.94 Million USD | 736.18% |
| 2003 Q1 | 17.21 Million USD | 42.59% |
| 2003 FY | 138.48 Million USD | 1047.08% |
| 2003 Q4 | 138.48 Million USD | -2.8% |
| 2002 Q1 | 12.93 Million USD | 5.5% |
| 2002 Q4 | 12.07 Million USD | 7.23% |
| 2002 FY | 12.07 Million USD | -1.55% |
| 2002 Q2 | 11.19 Million USD | -13.48% |
| 2002 Q3 | 11.25 Million USD | 0.58% |
| 2001 Q1 | 3.68 Million USD | -46.91% |
| 2001 Q2 | 5.32 Million USD | 44.44% |
| 2001 Q3 | 6.23 Million USD | 17.2% |
| 2001 Q4 | 12.26 Million USD | 96.65% |
| 2001 FY | 12.26 Million USD | 76.73% |
| 2000 Q1 | 4.75 Million USD | -7.99% |
| 2000 FY | 6.93 Million USD | 34.16% |
| 2000 Q4 | 6.93 Million USD | 88.97% |
| 2000 Q3 | 3.67 Million USD | 26.88% |
| 2000 Q2 | 2.89 Million USD | -39.19% |
| 1999 Q2 | 34 Million USD | 1900.0% |
| 1999 Q4 | 5.17 Million USD | -9.26% |
| 1999 FY | 5.17 Million USD | 146.29% |
| 1999 Q3 | 5.7 Million USD | -83.24% |
| 1999 Q1 | 1.7 Million USD | 0.0% |
| 1998 FY | 2.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | -462.891% |
| Alkermes plc | 933.53 Million USD | -102.462% |
| Agenus Inc. | 462.29 Million USD | -308.842% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 53.338% |
| Aptorum Group Limited | 5.25 Million USD | -35854.883% |
| Ardelyx, Inc. | 130.76 Million USD | -1345.404% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | -295.086% |
| Bicycle Therapeutics plc | 224.41 Million USD | -742.225% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -1351.543% |
| ChromaDex Corporation | 26.5 Million USD | -7030.127% |
| Chimerix, Inc. | 19.74 Million USD | -9472.317% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -5272.965% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -2504.564% |
| CRISPR Therapeutics AG | 346.76 Million USD | -445.049% |
| Precision BioSciences, Inc. | 140.92 Million USD | -1241.225% |
| Dyadic International, Inc. | 2.34 Million USD | -80649.074% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -11521.804% |
| Fortress Biotech, Inc. | 165.93 Million USD | -1039.005% |
| Lantern Pharma Inc. | 2.73 Million USD | -68888.08% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -2544.172% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -53461.952% |
| Incyte Corporation | 1.59 Billion USD | -18.702% |
| IO Biotech, Inc. | 17.55 Million USD | -10665.858% |
| Jaguar Health, Inc. | 45.86 Million USD | -4020.817% |
| Novavax, Inc. | 2.57 Billion USD | 26.522% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -5141.705% |
| Opthea Limited | 264.6 Million USD | -614.303% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -1346.024% |
| ContextLogic Inc. | 206 Million USD | -817.502% |
| MiMedx Group, Inc. | 96.33 Million USD | -1862.062% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -3835.809% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -53459.493% |
| NextCure, Inc. | 14.99 Million USD | -12502.881% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -46660.366% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -28206.934% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -3943.848% |
| Vaxcyte, Inc. | 167.44 Million USD | -1028.734% |
| PDS Biotechnology Corporation | 33.25 Million USD | -5582.812% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -703.547% |
| Pharming Group N.V. | 244.07 Million USD | -674.381% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -15753.498% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -1379.02% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -28505.633% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -28505.633% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -2192.837% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -28351.814% |
| Acelyrin, Inc. | 86.35 Million USD | -2088.753% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -145373.703% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -13044.544% |
| Summit Therapeutics Inc. | 125.25 Million USD | -1408.941% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -19839.382% |
| Senti Biosciences, Inc. | 52.57 Million USD | -3495.241% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -2648.09% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -1147.462% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -96528.528% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -141417.292% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -733.24% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -20077.794% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -730.994% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | -282.208% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -17217.702% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -6770.176% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -15514.217% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | -288.42% |
| Immix Biopharma, Inc. | 3.72 Million USD | -50683.563% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -4898.556% |
| MEI Pharma, Inc. | 8.35 Million USD | -22521.831% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -6414.058% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -443.775% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -1195.72% |
| Fortress Biotech, Inc. | 165.93 Million USD | -1039.005% |
| Precigen, Inc. | 41.64 Million USD | -4438.599% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -3685.408% |
| AlloVir, Inc. | 45.01 Million USD | -4098.72% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -1350.129% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -1271.592% |
| ImmuCell Corporation | 18.81 Million USD | -9945.45% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -6596.145% |
| Onconetix, Inc. | 23.18 Million USD | -8053.501% |
| PureTech Health plc | 125.58 Million USD | -1405.024% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -21017.922% |
| Elevation Oncology, Inc. | 34.28 Million USD | -5413.255% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -77202.822% |
| Seer, Inc. | 39.36 Million USD | -4701.357% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -2956.658% |
| Innoviva, Inc. | 568.55 Million USD | -232.433% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -6841.582% |
| ESSA Pharma Inc. | 3.49 Million USD | -53977.7% |
| GlycoMimetics, Inc. | 6.9 Million USD | -27283.856% |
| GT Biopharma, Inc. | 6.63 Million USD | -28394.708% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -614.873% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -594.14% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -2149.368% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -19237.569% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -6856.656% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -58492.282% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -2462.194% |
| Aptose Biosciences Inc. | 15.8 Million USD | -11855.783% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -17020.541% |
| Soligenix, Inc. | 7.27 Million USD | -25880.467% |
| Century Therapeutics, Inc. | 175.94 Million USD | -974.254% |
| Kura Oncology, Inc. | 51.66 Million USD | -3558.499% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -1458.396% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -45630.801% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -28477.191% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -648.246% |
| Autolus Therapeutics plc | 263.9 Million USD | -616.182% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -17931.425% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -2026.978% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -3930.052% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -435.645% |
| GRI Bio, Inc. | 2.69 Million USD | -69979.867% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -233359.612% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -5979.103% |
| IGM Biosciences, Inc. | 220.17 Million USD | -758.425% |
| INmune Bio, Inc. | 18.86 Million USD | -9920.433% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -636.923% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -6994.315% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -69428.025% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -57518.925% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -3133.349% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -1865.551% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -613.942% |
| Coherus BioSciences, Inc. | 823.02 Million USD | -129.646% |
| Verastem, Inc. | 71.18 Million USD | -2555.13% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -3743.448% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -4799.305% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -3762.613% |
| Histogen Inc. | 5.69 Million USD | -33076.303% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -42996.768% |
| Surrozen, Inc. | 8.14 Million USD | -23105.083% |
| Organovo Holdings, Inc. | 2.74 Million USD | -68679.258% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -602100.358% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -3261.297% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -11346.548% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -3598.519% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -228477.959% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -1391.461% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -17378.506% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -1152.612% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -72389.601% |
| Apollomics, Inc. | 14.15 Million USD | -13254.441% |
| Amarin Corporation plc | 279.58 Million USD | -576.016% |
| Mesoblast Limited | 188.79 Million USD | -901.099% |
| Turnstone Biologics Corp. | 14.14 Million USD | -13259.16% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -945.453% |
| Synaptogenix, Inc. | 5.52 Million USD | -34081.474% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -28330.415% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -1011.091% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -21987.313% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -107448.738% |
| Exelixis, Inc. | 678.44 Million USD | -178.586% |
| Better Therapeutics, Inc. | 23.84 Million USD | -7827.414% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -1052.149% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | -218.079% |
| NLS Pharmaceutics AG | 10.68 Million USD | -17596.797% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -116310.161% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -4755.381% |
| Gritstone bio, Inc. | 125.91 Million USD | -1401.008% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -12778.536% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -37042.711% |
| Avid Bioservices, Inc. | 275.66 Million USD | -585.627% |
| Insmed Incorporated | 1.66 Billion USD | -13.738% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -24465.221% |
| MediWound Ltd. | 27.18 Million USD | -6852.051% |
| OmniAb, Inc. | 87.4 Million USD | -2062.533% |
| Alector, Inc. | 487.66 Million USD | -287.569% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -368.466% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -10158.095% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -4825.479% |
| Zai Lab Limited | 240.17 Million USD | -686.942% |
| Revance Therapeutics, Inc. | 630.05 Million USD | -199.981% |
| Aura Biosciences, Inc. | 29.22 Million USD | -6366.808% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -1887.919% |
| Immunic, Inc. | 25.36 Million USD | -7350.544% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -2629.872% |
| Veracyte, Inc. | 93.71 Million USD | -1916.724% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -72131.188% |
| FibroGen, Inc. | 585.72 Million USD | -222.685% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -10773.002% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -289307.971% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -33319.999% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 75.314% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -22955.062% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -2149.475% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1017.813% |
| Galecto, Inc. | 5.89 Million USD | -31956.547% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -22715.717% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 27.816% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -6457.678% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -14875.469% |
| XBiotech Inc. | 8.39 Million USD | -22408.682% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -12778.536% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -3454.069% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -420.524% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -6930.405% |
| Theravance Biopharma, Inc. | 169 Million USD | -1018.349% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | -55.483% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | -277.689% |
| Vaxxinity, Inc. | 30.94 Million USD | -6007.982% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | -94.352% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -31238.426% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | -153.619% |
| NexImmune, Inc. | 5.08 Million USD | -37074.818% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -508808.06% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -61368.209% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 73.406% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -36571.381% |
| Scopus BioPharma Inc. | 7.45 Million USD | -25254.762% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -7088.157% |
| Ainos, Inc. | 7.39 Million USD | -25461.225% |
| Pluri Inc. | 34.11 Million USD | -5440.731% |
| Prothena Corporation plc | 135.01 Million USD | -1299.864% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -677.47% |
| Celularity Inc. | 102.92 Million USD | -1736.27% |
| Rallybio Corporation | 9.43 Million USD | -19930.246% |
| Cue Biopharma, Inc. | 24.44 Million USD | -7631.863% |
| MeiraGTx Holdings plc | 319.99 Million USD | -490.658% |
| Omeros Corporation | 403.25 Million USD | -368.703% |
| Humacyte, Inc. | 114.67 Million USD | -1548.154% |
| Immunocore Holdings plc | 228.15 Million USD | -728.397% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -38670.338% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -2362.932% |
| Blueprint Medicines Corporation | 918.64 Million USD | -105.745% |
| CalciMedica, Inc. | 4.02 Million USD | -46822.89% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -10730.014% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -1126.169% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -2102.424% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -580.382% |
| Pulmatrix, Inc. | 15.96 Million USD | -11740.218% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -11882.844% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -7581.273% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -653.586% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -3621.604% |
| Cytokinetics, Incorporated | 1.21 Billion USD | -56.12% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -5846.745% |
| Nutriband Inc. | 1.07 Million USD | -175080.343% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -17675.36% |
| Vor Biopharma Inc. | 59.1 Million USD | -3097.844% |
| Roivant Sciences Ltd. | 773.95 Million USD | -144.208% |
| Evogene Ltd. | 17.99 Million USD | -10406.137% |
| ProKidney Corp. | 29.21 Million USD | -6369.243% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -2525.841% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -267999.231% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | -0.06% |
| CorMedix Inc. | 11.91 Million USD | -15759.447% |
| BioLineRx Ltd. | 50.7 Million USD | -3627.77% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -1164.597% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -2037.079% |
| Atai Life Sciences N.V. | 49.16 Million USD | -3744.543% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -5967.14% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -10422.514% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -1416.459% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -33328.617% |
| MediciNova, Inc. | 3.89 Million USD | -48468.117% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -10240.03% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -125548.35% |
| GeoVax Labs, Inc. | 3.51 Million USD | -53596.531% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -375.774% |
| Biomea Fusion, Inc. | 30.69 Million USD | -6058.534% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 30.557% |
| Mereo BioPharma Group plc | 15.96 Million USD | -11740.96% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -5957.671% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -3120.731% |
| Absci Corporation | 58.3 Million USD | -3141.723% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -9822.585% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -5794.997% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -2461.396% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -2060.481% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -5496.843% |
| Allakos Inc. | 74.79 Million USD | -2427.047% |
| Imunon, Inc. | 8.53 Million USD | -22056.617% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -8299.867% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -1546.216% |
| BioAtla, Inc. | 48.98 Million USD | -3758.355% |
| NLS Pharmaceutics AG | 10.68 Million USD | -17596.797% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -67912.019% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -1347.164% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -13196.194% |
| XOMA Corporation | 145.58 Million USD | -1198.292% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -5514.3% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -2648.81% |
| aTyr Pharma, Inc. | 31.59 Million USD | -5881.751% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -2957.202% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -4103.389% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -3804.909% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -65755.54% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -23068.054% |
| Akari Therapeutics, Plc | 4.58 Million USD | -41131.545% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -10558.321% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -14.586% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -467841.709% |
| UroGen Pharma Ltd. | 243.52 Million USD | -676.13% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -488.642% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -68341.583% |
| Orgenesis Inc. | 35.53 Million USD | -5218.852% |
| Entera Bio Ltd. | 1.37 Million USD | -136959.753% |
| GH Research PLC | 6.7 Million USD | -28105.551% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -27694.912% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -9939.594% |
| Xencor, Inc. | 283.55 Million USD | -566.547% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -63204.077% |
| Replimune Group, Inc. | 113.21 Million USD | -1569.453% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -50205.859% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -1725.61% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -467841.709% |
| Portage Biotech Inc. | 4.45 Million USD | -42373.124% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -125548.35% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -8099.8% |
| OncoCyte Corporation | 49.29 Million USD | -3733.936% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -45588.738% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -236902.122% |
| Purple Biotech Ltd. | 10 Million USD | -18791.094% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -32565.987% |
| scPharmaceuticals Inc. | 57.26 Million USD | -3200.77% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -15157.11% |
| HilleVax, Inc. | 78.9 Million USD | -2295.232% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -37326.812% |
| Tharimmune, Inc. | 1.81 Million USD | -104032.567% |
| Genprex, Inc. | 3.25 Million USD | -57980.307% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -6869.483% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -35997.288% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -917401.942% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -527041.136% |
| OKYO Pharma Limited | 7.42 Million USD | -25369.522% |
| Savara Inc. | 37.19 Million USD | -4981.883% |
| Curis, Inc. | 57.61 Million USD | -3180.66% |
| Daré Bioscience, Inc. | 26.32 Million USD | -7078.368% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -4721.592% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -130790.166% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -8978.505% |
| BeiGene, Ltd. | 2.23 Billion USD | 15.386% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -8777.744% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -620.303% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -8784.338% |
| Erasca, Inc. | 78.61 Million USD | -2304.312% |
| bluebird bio, Inc. | 424.62 Million USD | -345.112% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -288346.888% |
| DBV Technologies S.A. | 42.8 Million USD | -4316.014% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -288346.888% |
| Moderna, Inc. | 4.57 Billion USD | 58.66% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -26920.071% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -114033.696% |
| Molecular Templates, Inc. | 31.17 Million USD | -5963.501% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -10972.373% |
| Travere Therapeutics, Inc. | 588.1 Million USD | -221.381% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -1418.055% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -6788.705% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -5084.48% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -3297.239% |
| MacroGenics, Inc. | 154.2 Million USD | -1125.66% |
| RenovoRx, Inc. | 4.46 Million USD | -42220.958% |
| Adicet Bio, Inc. | 37.12 Million USD | -4991.74% |
| Prime Medicine, Inc. | 60.78 Million USD | -3009.664% |
| Aditxt, Inc. | 28.53 Million USD | -6524.433% |
| Adagene Inc. | 45.16 Million USD | -4084.374% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -1045856.58% |
| Quantum-Si incorporated | 26.63 Million USD | -6997.195% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | -170.95% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -62023.008% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -1544.083% |
| SciSparc Ltd. | 1.59 Million USD | -118398.683% |
| Vericel Corporation | 127.7 Million USD | -1380.016% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -33863.881% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -2114.264% |
| Generation Bio Co. | 171.63 Million USD | -1001.238% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -16264.104% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -4418.309% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -647.95% |
| Invivyd, Inc. | 51.71 Million USD | -3554.891% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -1954.92% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -28954.282% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -2403.515% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -185017.924% |
| 2seventy bio, Inc. | 310.12 Million USD | -509.447% |
| ADMA Biologics, Inc. | 193.97 Million USD | -874.375% |
| Clene Inc. | 38.95 Million USD | -4752.389% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -5130.845% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -635.498% |
| GeoVax Labs, Inc. | 3.51 Million USD | -53596.531% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -893.39% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -15418.115% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -853.023% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -15398.852% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -3828.528% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -3476.87% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -411.027% |
| Evaxion Biotech A/S | 17.61 Million USD | -10628.288% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -1074.465% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -1133.829% |
| Trevena, Inc. | 48.26 Million USD | -3816.236% |
| Surrozen, Inc. | 8.14 Million USD | -23105.083% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -8652.276% |
| Cingulate Inc. | 10.36 Million USD | -18142.241% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -68629.236% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -4968.256% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -52598.828% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -14273.034% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -495.854% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -7506.157% |
| Clearmind Medicine Inc. | 3.61 Million USD | -52255.95% |
| Kronos Bio, Inc. | 54.2 Million USD | -3387.12% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -3917.716% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -8204.377% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -9316.84% |
| Statera Biopharma, Inc. | 22.67 Million USD | -8234.875% |
| ImmunityBio, Inc. | 1.09 Billion USD | -73.338% |
| Korro Bio, Inc. | 51.75 Million USD | -3552.137% |
| Kineta, Inc. | 7.22 Million USD | -26070.784% |
| BioVie Inc. | 9.7 Million USD | -19380.815% |
| Codexis, Inc. | 49.94 Million USD | -3684.195% |
| Celularity Inc. | 102.92 Million USD | -1736.27% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -1863.754% |
| Celcuity Inc. | 51.45 Million USD | -3573.569% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -547433.851% |
| Cibus, Inc. | 206.11 Million USD | -816.981% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -4349.803% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -7075.876% |
| IN8bio, Inc. | 8.77 Million USD | -21446.443% |
| Kodiak Sciences Inc. | 213.59 Million USD | -784.894% |
| Annexon, Inc. | 47.11 Million USD | -3911.321% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -2010.825% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -1861.207% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -13707.101% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 27.4% |
| Eyenovia, Inc. | 19.78 Million USD | -9455.244% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -967.309% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -24506.874% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -7742.873% |
| Arcellx, Inc. | 339.75 Million USD | -456.304% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -15785.477% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -669.754% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -19664.237% |
| Moolec Science SA | 13.94 Million USD | -13453.286% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -4279.992% |
| Geron Corporation | 146.12 Million USD | -1193.432% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -3640.311% |
| Royalty Pharma plc | 6.29 Billion USD | 69.988% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -4651.745% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -641888.954% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -76722.657% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -899.204% |
| Humacyte, Inc. | 114.67 Million USD | -1548.154% |
| Structure Therapeutics Inc. | 29.05 Million USD | -6405.985% |
| 89bio, Inc. | 59.96 Million USD | -3052.034% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -7042.251% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -157931.271% |
| Genelux Corporation | 8.42 Million USD | -22347.197% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -27467.882% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -1286.493% |
| Notable Labs, Ltd. | 4.42 Million USD | -42593.788% |
| Liquidia Corporation | 73.13 Million USD | -2484.23% |
| Mustang Bio, Inc. | 17.61 Million USD | -10627.363% |
| Immunovant, Inc. | 48.95 Million USD | -3760.799% |
| Quantum-Si incorporated | 26.63 Million USD | -6997.195% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -4824.196% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -60810.538% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -2458.934% |
| Acasti Pharma Inc. | 11.55 Million USD | -16254.192% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -8260.211% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -69428.025% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -5025.292% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -138584.748% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -30904.823% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -7510.445% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -8052.407% |
| PepGen Inc. | 34.63 Million USD | -5357.694% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -15463.686% |
| United Therapeutics Corporation | 1.18 Billion USD | -59.876% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -26962.629% |
| Solid Biosciences Inc. | 38.45 Million USD | -4814.593% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -21987.313% |
| Immuneering Corporation | 12 Million USD | -15639.491% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -602100.358% |
| Silo Pharma, Inc. | 1.56 Million USD | -120341.607% |
| Belite Bio, Inc | 4.21 Million USD | -44783.733% |
| XOMA Corporation | 145.58 Million USD | -1198.292% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -77744.069% |
| Bionomics Limited | 10.15 Million USD | -18505.236% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -8694.63% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -8148.828% |
| uniQure N.V. | 624.01 Million USD | -202.884% |
| Cassava Sciences, Inc. | 14.19 Million USD | -13214.928% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -1045856.58% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -1010.594% |
| Forte Biosciences, Inc. | 3.66 Million USD | -51456.301% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -725217.461% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -27913.25% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -24506.874% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -10773.002% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -17784.69% |
| Altimmune, Inc. | 16.54 Million USD | -11326.48% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -205.98% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -8148.828% |
| Compugen Ltd. | 55.77 Million USD | -3288.712% |
| Peak Bio, Inc. | 20.75 Million USD | -9007.218% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -1611.029% |
| Benitec Biopharma Inc. | 4.96 Million USD | -37990.568% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -1097.427% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -2414.239% |
| Zura Bio Limited | 21.29 Million USD | -8776.827% |
| PolyPid Ltd. | 17.46 Million USD | -10720.094% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -1581.558% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -2414.239% |
| Instil Bio, Inc. | 99.8 Million USD | -1793.823% |
| argenx SE | 444.95 Million USD | -324.778% |
| Immunome, Inc. | 28.65 Million USD | -6495.206% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -22570.673% |
| Verona Pharma plc | 58.84 Million USD | -3112.138% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -12959.172% |
| Shattuck Labs, Inc. | 14.85 Million USD | -12619.927% |
| CervoMed Inc. | 2.59 Million USD | -72713.491% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -38678.293% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -14740.248% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -17840.712% |
| Moolec Science SA | 13.94 Million USD | -13453.286% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -80550.769% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -3299.665% |
| AnaptysBio, Inc. | 364.28 Million USD | -418.838% |
| Design Therapeutics, Inc. | 11.95 Million USD | -15708.414% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -14801.088% |
| NeurAxis, Inc. | 1.91 Million USD | -98714.004% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -4755.256% |
| Lumos Pharma, Inc. | 13.33 Million USD | -14075.759% |
| Achilles Therapeutics plc | 19.08 Million USD | -9802.31% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -12959.172% |
| 180 Life Sciences Corp. | 5.38 Million USD | -34984.104% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -7912.781% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -8204.377% |
| Nutriband Inc. | 1.07 Million USD | -175080.343% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -6077.051% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -12924.974% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -371.013% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -5720.386% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -14384.176% |
| Palisade Bio, Inc. | 2.73 Million USD | -68905.257% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -35880.468% |
| Beam Therapeutics Inc. | 478.38 Million USD | -295.091% |
| Neurogene Inc. | 36.54 Million USD | -5071.288% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -374.946% |
| AEON Biopharma, Inc. | 159.88 Million USD | -1082.104% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -3866.535% |
| Sesen Bio, Inc. | 30.98 Million USD | -6000.097% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -7180.359% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -24761.882% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -865.604% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -884.111% |
| Athira Pharma, Inc. | 30.05 Million USD | -6188.232% |
| Vaccinex, Inc. | 5.94 Million USD | -31708.381% |
| HCW Biologics Inc. | 15.05 Million USD | -12456.877% |
| XOMA Corporation | 145.58 Million USD | -1198.292% |
| Nektar Therapeutics | 267.04 Million USD | -607.763% |
| Arvinas, Inc. | 644.6 Million USD | -193.213% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -10558.321% |
| Merus N.V. | 102.15 Million USD | -1750.255% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -1191.462% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -1887.021% |
| Rezolute, Inc. | 11.73 Million USD | -16007.5% |
| Clene Inc. | 38.95 Million USD | -4752.389% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -66278.706% |
| BeyondSpring Inc. | 48.26 Million USD | -3815.668% |
| Synlogic, Inc. | 32.89 Million USD | -5645.718% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -12834.059% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -115570.379% |
| Peak Bio, Inc. | 20.75 Million USD | -9007.218% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -2878.386% |
| Krystal Biotech, Inc. | 39.71 Million USD | -4659.163% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -401.814% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -1798.235% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -436678.47% |
| MannKind Corporation | 721.36 Million USD | -162.01% |
| Ikena Oncology, Inc. | 22.33 Million USD | -8362.297% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -90506.616% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -1742.337% |
| Gossamer Bio, Inc. | 249.14 Million USD | -658.61% |
| CohBar, Inc. | 1.03 Million USD | -182754.539% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -17582.234% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -9822.585% |
| Legend Biotech Corporation | 589.93 Million USD | -220.385% |
| Mural Oncology plc | 37.92 Million USD | -4883.268% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -1324.993% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -82243.382% |
| Disc Medicine, Inc. | 22.87 Million USD | -8162.531% |
| Champions Oncology, Inc. | 28.03 Million USD | -6641.766% |
| REGENXBIO Inc. | 262.22 Million USD | -620.767% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -56162.458% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -14979.416% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -13971.668% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -8813.247% |
| Vaxart, Inc. | 34.02 Million USD | -5454.898% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -9169.849% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -6524.358% |
| Cellectis S.A. | 249.57 Million USD | -657.309% |
| Longeveron Inc. | 5.33 Million USD | -35314.165% |
| Repare Therapeutics Inc. | 41.81 Million USD | -4419.606% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 21.419% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -3030.887% |
| Revolution Medicines, Inc. | 262.39 Million USD | -620.303% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -89603.56% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -21811.129% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -15916.049% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -13359.047% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -87768.619% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 63.298% |
| Denali Therapeutics Inc. | 122.96 Million USD | -1437.092% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -33863.881% |
| Veru Inc. | 32.81 Million USD | -5660.128% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -27415.708% |
| Cingulate Inc. | 10.36 Million USD | -18142.241% |
| Passage Bio, Inc. | 39.26 Million USD | -4713.952% |
| Context Therapeutics Inc. | 4.19 Million USD | -44990.232% |
| Exicure, Inc. | 8.54 Million USD | -22008.481% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -6305.226% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -17924.547% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -8475.174% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -1059.642% |
| Nuvalent, Inc. | 31.82 Million USD | -5839.27% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -29610.23% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -2899.038% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -10400.3% |
| OmniAb, Inc. | 87.4 Million USD | -2062.533% |
| Anew Medical, Inc. | 8.24 Million USD | -22832.542% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -4836.272% |
| Lipocine Inc. | 2.63 Million USD | -71720.686% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -7094.176% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -4600.224% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -6994.315% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -2093.809% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -34894.52% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -2184.136% |
| Ocugen, Inc. | 23.98 Million USD | -7780.807% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -3972.778% |
| Q32 Bio Inc. | 233.12 Million USD | -710.737% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -20747.717% |
| Alumis Inc. Common Stock | 53.5 Million USD | -3432.679% |
| Equillium, Inc. | 27.95 Million USD | -6660.575% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -814.873% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -33491.017% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -30717.934% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -1101.362% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -2622.126% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -18849.428% |
| Dominari Holdings Inc. | 4.63 Million USD | -40677.864% |
| Edesa Biotech, Inc. | 1.84 Million USD | -102529.02% |
| vTv Therapeutics Inc. | 29.56 Million USD | -6292.444% |
| Bio-Techne Corporation | 744.34 Million USD | -153.923% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1398.865% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -448.707% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -4558.174% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -6427.106% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -1946.399% |
| Nkarta, Inc. | 105.6 Million USD | -1689.824% |
| BioCardia, Inc. | 4.59 Million USD | -41077.647% |
| Iterum Therapeutics plc | 32.66 Million USD | -5686.706% |